title: [Prognostic value of maximum standard uptake on pretreatment 18F-FDG PET/CT scan in newly diagnosed diffuse large B cell lymphoma].
abstract: OBJECTIVE
  To evaluate the prognostic value of maximum standard uptake (SUVmax) on pretreatment (18)F-fluoro-2-deoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT) scan in patients with newly diagnosed diffuse large B cell lymphoma (DLBCL).
  
  
  METHODS
  The clinical data of 39 DLBCL patients undergoing a PET/CT scan at pre-treatment from December 2009 to October 2011 were analyzed retrospectively. SUVmax on PET/CT was evaluated by SPSS 13.0 for the associations with patient characteristics, prognostic factors, treatment efficacy and survival time.
  
  
  RESULTS
  The median SUVmax was higher in non-germinal center B cell-like (non-GCB) patients than that in GCB ones (18.0(2.2 - 40.5) vs 11.6 (5.3 - 18.7), P = 0.039). No difference of SUVmax was observed between the patients with and without bulky disease (P = 0.539). SUVmax was not associated with such patient characteristics as international protein index, age, stage, Eastern Cooperative Oncology Group performance status, lactate dehydrogenase, number of extranodal involvement and Ki-67 (all P > 0.05). No significant difference in median SUVmax existed between complete remission (CR) and non-CR patients (P = 0.312). The difference of SUVmax was insignificant for the patients with efficacy and no efficacy (P = 0.243). With the cut-off values of 10, 15, 20, the CR rate, response rate, 2-year progression-free survival (PFS) rate and 2-year overall survival (OS) rate were not different between the patients with SUVmax below and above cut-off value (all P > 0.05).
  
  
  CONCLUSIONS
  The prognostic value of SUVmax on PET/CT is indeterminate. And it can not be used to predict the patient prognosis.
authors: Peking University Cancer Hospital & Institute, Department of Lymphoma, Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education), Beijing 100142, China.
authors: Zhi-tao
authors: ZT
authors: Ying
authors: Xue-juan
authors: XJ
authors: Wang
authors: Yu-qin
authors: YQ
authors: Song
authors: Wen
authors: W
authors: Zheng
authors: Xiao-pei
authors: XP
authors: Wang
authors: Yan
authors: Y
authors: Xie
authors: Ning-jing
authors: NJ
authors: Lin
authors: Mei-feng
authors: MF
authors: Tu
authors: Ling-yan
authors: LY
authors: Ping
authors: Wei-Ping
authors: WP
authors: Liu
authors: Li-juan
authors: LJ
authors: Deng
authors: Chen
authors: C
authors: Zhang
authors: Zhi
authors: Z
authors: Yang
authors: Jun
authors: J
authors: Zhu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000008:administration & dosage*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000000981:diagnostic imaging* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods* / Q000592:standards; D011379:Prognosis; D012189:Retrospective Studies
chemical_list: D019788:Fluorodeoxyglucose F18